Dynamic contrast-enhanced MRI in the estimation of tumor angiogenesis and pathologic grading of extrahepatic cholangiocarcinoma
10.3760/cma.j.issn.1007-8118.2014.01.003
- VernacularTitle:磁共振动态增强成像评价肝外胆管癌血管生成及病理分级
- Author:
Yu WANG
;
Qingan XIA
;
Yuxin ZHANG
;
Peng PENG
;
Haiping WANG
;
Menghua MA
- Publication Type:Journal Article
- Keywords:
Bile duct neoplasms;
Magnetic resonance imaging;
Vascular endothelial growth factors;
Pathology
- From:
Chinese Journal of Hepatobiliary Surgery
2014;20(1):6-10
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the role of dynamic contrast-enhanced MRI (DCE-MRI) in the estimation of tumor angiogenesis and pathologic grading of extrahepatic cholangiocarcinoma.Methods Routine preoperative MRI and DCE-MRI scanning were performed on 57 patients with extrahepatic cholangiocarcinoma.The early signal enhancement ratio (eSER) and delayed signal enhancement ratio (dSER) of DCE-MRI were calculated.Microvessel density (MVD) and vascular endothelial growth factor (VEGF) expressions were detected in the extrahepatic cholangiocarcinoma tissue samples using immunohistochemical methods.The relations between the eSER or dSER and MVD,VEGF and the pathological grading of extrahepatic cholangiocarcinoma were analyzed.Results There was a positive correlation between the eSER or dSER and MVD of extrahepatic cholangiocarcinoma (r =0.62,P ＜ 0.05 ; r =0.45,P ＜ 0.05).The eSER of extrahepatic cholangiocarcinoma with a positive VEGF expression was higher than those with a negative VEGF expression (t =3.53,P ＜ 0.05).There was no significant difference in dSER between the positive VEGF expression group and the negative VEGF expression group (t =1.35,P ＞0.05).There was no significant difference in the eSER or dSER among the different differentiated extrahepatic cholangiocarcinoma (F =2.65,P ＞ 0.05 ; F =2.23,P ＞ 0.05).Conclusions The eSER and dSER reflected tumor angiogenesis of extrahepatic cholangiocarcinoma,and DCE-MRI contributed to the evaluation of biological features of extrahepatic cholangiocarcinoma in vivo.
